Anti-RSV prophylaxis efficacy for infants and young children with cystic fibrosis in Ireland

RATIONALE: There is limited evidence supporting the routine use of palivizumab in paediatric cystic fibrosis (CF) patients to reduce respiratory syncytial virus (RSV) infection and related hospitalisation. Despite this, anti-RSV prophylaxis is increasingly common. This is the first report from Irela...

Descripción completa

Detalles Bibliográficos
Autores principales: Linnane, Barry, Kiernan, Miranda G., O’Connell, Nuala H., Kearse, Linda, Dunne, Colum P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4607252/
https://www.ncbi.nlm.nih.gov/pubmed/26473032
http://dx.doi.org/10.1186/s40248-015-0029-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4607252/
https://www.ncbi.nlm.nih.gov/pubmed/26473032
http://dx.doi.org/10.1186/s40248-015-0029-9

Ejemplares similares